Campaigns blog

Find out how MS campaigners are making a difference across the UK.

Posts in Disease modifying drugs (DMDs)

New law could improve access to off-patent drugs

The Access to Medical Treatments (Innovations) Bill has now become law. This is an important milestone in our Treat Me Right campaign as it could improve access to repurposed off-patent drugs for people with MS.

One of the Act’s main clauses will introduce a database of innovative treatments including evidence about repurposed off-patent drugs.

The Risk Sharing Scheme - what does it mean for me?

What is the Risk Sharing Scheme?

The Risk Sharing Scheme (RSS) is a patient access scheme for treatments. It was set up in 2002 in response to a National Institute for Health and Care Excellence (NICE) decision that two licensed MS medicines were not cost effective and should not be made available on the NHS.

Why we patently need the Off-patent Drugs Bill

Picture the scene: a researcher discovers that an old drug originally developed and patented for another condition can also be used to effectively treat multiple sclerosis. This is known as an “off-patent drug”. Clinical trials are conducted, and early results seem to confirm this too.

Effective treatments must remain available on NHS

Stethoscope in doctor's pocket

Data gathered by the Risk Sharing Scheme (RSS) over six years has proved that four treatments for relapsing remitting MS slow progression, and are cost effective.

How do new medicines get approved in England and Wales?

Orange and white capsulesBefore new medicines are made available in England, they undergo an appraisal by the National Institute for Health and Care Excellence (NICE).

We take a look at the appraisal proccess in England, what happens if a medicine is not recommended by NICE and how you can campaign to access treatments.

Putting a price on health

In 2010 the coalition government announced that a new system for assessing the cost of medicines, known as value-based pricing (VBP), would be introduced in England and Wales.

It was initially proposed to help increase access to medicines and improve innovation in the development of new drugs. 

What's new?